Pivot Pharmaceuticals Strengthens Scientific Advisory Board

BOSTON, MA and VANCOUVER, BC--(Marketwired - Dec 10, 2015) - Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) ("Pivot" or the "Company"), an emerging biotechnology company engaged in the development of therapeutics to address unmet medical needs in women's health including oncology and urology, is pleased to announce the appointments of Steven Grossman, M.D., Ph.D., and Grannum Sant, M.D., F.R.C.S., F.A.C.S., to the Company's Scientific Advisory Board (SAB).

Dr. Steven Grossman serves as the Dianne Nunnally Hoppes Chair in Cancer Research and is Professor & Chair of the Division of Hematology, Oncology and Palliative Care at Virginia Commonwealth University (VCU). He is also the Deputy Director of the VCU Massey Cancer Center and joins Pivot's SAB as its Chair, succeeding Dr. Pravin Chaturvedi, who has assumed his new role as President & Chief Executive Officer of Pivot. Dr. Grossman is a renowned physician-scientist with a long standing interest in basic and translational initiatives involving response of tumor cells to DNA damage to improve therapeutic benefit in cancer patients. He received both his PhD and MD degrees from the University of Chicago and has an undergraduate degree in biology from Princeton University. Dr. Grossman completed a residency in internal medicine at the Harvard Medical School affiliated Brigham and Women's Hospital in Boston, and completed his post-doctoral fellowships at Harvard Medical School with Dr. Elliot Kieff, and in medical oncology at the Dana-Farber Cancer Institute with Dr. David Livingston.

Dr. Grannum Sant is a renowned key opinion leader (KOL) in the fields of urology and oncology in men's and women's health. He served as the Professor and Chair of Urology at Tufts University School of Medicine prior to joining the pharmaceutical industry as the Vice-President of Medical Affairs in Oncology and Urology at Sanofi-Aventis. He subsequently served as the Head of US and Global Medical Affairs at Genzyme and has retained his academic appointment as Professor of Urology at Tufts University School of Medicine. He currently serves as a Senior Medical Director at OPKO Urology, chairs the Scientific Advisory Board for Cellanyx Diagnostics, and is a member of EmpiraMed's SAB. Dr. Sant is a board certified physician in adult and pediatric urology and is the President-Elect of the Academy of Physicians in Clinical Research. He received his medical degree from Trinity College in Dublin (Ireland) and completed his residencies in general surgery at Albert Einstein College of Medicine (NY) and Royal College of Surgeons (Scotland). He subsequently completed his residency in urology at Tufts University School of Medicine and received his Fellowships from the Royal College of Surgeons (FRCS) and American College of Surgeons (FACS). Dr. Sant is an accomplished physician-scientist and has published widely in the fields of urology and cystitis and received multiple research grants for his research initiatives.

Dr. Pravin Chaturvedi said, "I am extremely pleased that both Drs. Grossman and Sant have joined Pivot's SAB. I am looking forward to their support and leadership for our drug programs in cancer and urological indications focused on women's health. They both have a deep experience in clinical research and development and have also partnered with the biotech and pharmaceutical industries towards advancement of novel therapies in the fields of oncology and urology."

"I am excited to be joining the Scientific Advisory Board of Pivot Pharmaceuticals," said Dr. Steven Grossman. "I have a longstanding interest in understanding how DNA repair mutations in tumors can be leveraged to sensitize the DNA damage response, and I am looking forward to working with the Pivot team to address unmet medical needs in gynecological cancers such as metastatic endometrial cancer that have such DNA repair mutations and need new therapies. I am also pleased to collaborate with the experienced leadership team of Pivot Pharmaceuticals as it develops novel therapies to address these unmet medical needs."

"I am delighted to be a part of the Pivot SAB," said Dr. Grannum Sant. "As a longstanding member of the urology and oncology community, I am pleased that Pivot is focused on developing new therapies for unmet medical needs in gynecological disturbances and gynecological cancers. There remains a critical need for new therapies in improving the clinical outcomes for these patients."

About Pivot Pharmaceuticals, Inc.

Pivot is an emerging pharmaceutical company engaged in the development of novel therapies to address unmet medical needs in women's health including oncology and urology. The Company has a strategic emphasis on innovative drugs that will provide new treatment options for women's cancers as well as for unmet gynecological and urological problems. Pivot has a portfolio of novel anticancer candidates for the treatment of gynecological cancers and it is developing novel treatments to address disturbances such as dysmenorrhea, kidney stones and lower urinary tract symptoms (LUTS). The Company has a global drug development platform that combines the strengths of the United States, Canada and India which allows accelerated drug development strategies to provide novel therapeutic options to address unmet medical needs in women's health. 

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot's products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.